Apomorphine - Harvard Scientific

Drug Profile

Apomorphine - Harvard Scientific

Alternative Names: Apomorphine hydrochloride - Harvard Scientific

Latest Information Update: 09 Jan 2004

Price : $50

At a glance

  • Originator BioSphere Technologies
  • Developer BioSphere Technologies; Harvard Scientific Corporation
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Female sexual dysfunction; Male sexual dysfunction

Most Recent Events

  • 09 Jan 2004 No development reported - Preclinical for Male sexual dysfunction in USA (PO)
  • 25 May 2001 Profile reviewed but no significant changes made
  • 25 May 2001 No-Development-Reported for Female sexual dysfunction in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top